Phaseline

Companies › Iksuda Therapeutics

Iksuda Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IKS014
anti-HER2 antibody-drug conjugate (MMAF payload)
ERBB2Phase 1Breast CancerDec 2026
IKS03
anti-CD19 antibody-drug conjugate with pyrrolobenzodiazepine cytotoxic payload
CD19Phase 1B-cell Non-Hodgkin LymphomaSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05872295IKS014Phase 1Breast CancerOncologyDec 2026
NCT05365659IKS03Phase 1B-cell Non-Hodgkin LymphomaOncologySep 2027

Targets

CD19 (1) ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics AstraZeneca Miltenyi Biomedicine Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.